Trials / Completed
CompletedNCT00740753
Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option
A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 339 (actual)
- Sponsor
- OHSU Knight Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Fewer than 15% of hepatoma patients are suitable candidates for surgical removal of their cancer. The purpose of this protocol is to provide supervised access at Oregon Health and Science University to Y-90 treatment to provide these patients access to an alternate therapy. The radioactive beads are placed directly near or into the liver tumor with the intention of destroying the tumor cells.
Detailed description
Patients receive Y-90 (yttrium) glass microspheres via percutaneous hepatic arterial infusion. Patients amy be retreated between 30-90 days after initial infusion. After completion of therapy, patients are followed for 30 days and then every 3 months for up to 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Yttrium 90 (TheraSphere) | Y-90 embedded glass microspheres |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2021-04-28
- Completion
- 2021-04-28
- First posted
- 2008-08-25
- Last updated
- 2022-09-30
Source: ClinicalTrials.gov record NCT00740753. Inclusion in this directory is not an endorsement.